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Abstract
Background: 17b-estradiol (E2) has been implicated to exert neuroprotective effects in the brain following cerebral
ischemia. Classically, E2 is thought to exert its effects via genomic signaling mediated by interaction with nuclear estrogen
receptors. However, the role and contribution of extranuclear estrogen receptors (ER) is unclear and was the subject of the
current study.
Methodology/Principal Findings: To accomplish this goal, we employed two E2 conjugates (E2 dendrimer, EDC, and E2-
BSA) that can interact with extranuclear ER and exert rapid nongenomic signaling, but lack the ability to interact with
nuclear ER due to their inability to enter the nucleus. EDC or E2-BSA (10 mM) was injected icv 60 min prior to global cerebral
ischemia (GCI). FITC-tagged EDC or E2-BSA revealed high uptake in the hippocampal CA1 region after icv injection, with a
membrane (extranuclear) localization pattern in cells. Both EDC and E2-BSA exerted robust neuroprotection in the CA1
against GCI, and the effect was blocked by the ER antagonist, ICI182,780. EDC and E2-BSA both rapidly enhanced activation
of the prosurvival kinases, ERK and Akt, while attenuating activation of the proapoptotic kinase, JNK following GCI, effects
that were blocked by ICI182,780. Administration of an MEK or PI3K inhibitor blocked the neuroprotective effects of EDC and
E2-BSA. Further studies showed that EDC increased p-CREB and BDNF in the CA1 region in an ERK- and Akt-dependent
manner, and that cognitive outcome after GCI was preserved by EDC in an ER-dependent manner.
Conclusions/Significance: In conclusion, the current study demonstrates that activation of extranuclear ER results in
induction of ERK-Akt-CREB-BDNF signaling in the hippocampal CA1 region, which significantly reduces ischemic neuronal
injury and preserves cognitive function following GCI. The study adds to a growing literature that suggests that extranuclear
ER can have important actions in the brain.
Citation: Yang L-c, Zhang Q-G, Zhou C-f, Yang F, Zhang Y-d, et al. (2010) Extranuclear Estrogen Receptors Mediate the Neuroprotective Effects of Estrogen in the
Rat Hippocampus. PLoS ONE 5(5): e9851. doi:10.1371/journal.pone.0009851
Editor: Alessandro Bartolomucci, University of Parma, Italy
Received January 20, 2010; Accepted March 4, 2010; Published May 7, 2010
Copyright:  2010 Yang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by a research grant (NS050730) (to DWB) from the National Institute of Neurological Diseases and Stroke (NINDS), NIH,
USA, and a research grant (to RMW) from the National Natural Science Foundation (30970664) (to RMW) of China and the Natural Science Foundation
(C2008000997) (to RMW) of Hebei Provinces of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rmwang1213@yahoo.com.cn (RMW); dbrann@mcg.edu (DWB)
. These authors contributed equally to this work.
Introduction
17b-Estradiol (E2) has been implicated to be neuroprotective
against a variety of neurodegenerative disorders, including stroke,
Alzheimer’s disease and Parkinson’s disease, although controversy
exists [1]. For instance, a number of studies have documented that
women are ‘‘protected’’ against stroke relative to men – at least
until the years of menopause, when E2 levels decline. Intriguingly,
stroke outcome in postmenopausal women has been shown in
several studies to be worse as compared to males, with
postmenopausal women having a significantly higher disability
and fatality rate as compared to men [2,3,4,5]. While there may be
many reasons for the worse stroke outcome in women, it is
interesting that the onset and diminished outcome of stroke in
women parallels the time period of falling E2 levels that occurs
after menopause. Numerous studies have shown that exogenous
administration of E2 dramatically reduces infarct volume following
focal or global cerebral ischemia in ovariectomized female mice,
rats and gerbils, and in male rats and gerbils [1,6,7,8,9,10]. Two
estrogen receptor (ER) isoforms have been identified to date, ERa
and ERb, both of which are expressed in the adult brain and thus
could mediate the neuroprotection by E2 [1,11,12]. ERa has been
implicated as particularly important in the neuroprotective effects
of E2, as evidenced by the fact that E2-mediated neuroprotection
against middle cerebral artery occlusion (MCAO)-induced cere-
bral ischemia is lost in OVX ERa knockout mice, but not ERb-
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antisense oligonucleotides significantly attenuate E2 neuroprotec-
tion in the hippocampal CA1 region following global cerebral
ischemia (GCI) [15]. However, use of purported selective ERa and
ERb agonists in the GCI model, suggested that both ER subtypes
may contribute to E2 neuroprotection in the hippocampal CA1
region of the brain [16].
It has been predominantly thought that E2 neuroprotection in
the brain is mediated principally by the ‘‘classical’’ nuclear ER-
mediated genomic signaling pathway, which involves E2 interac-
tion with nuclear ER and regulation of transcription of various
genes that mediate neuroprotection. For instance, E2 has been
shown to increase the expression of the anti-apoptotic gene, bcl-2,
in the ischemic penumbra following MCAO and global ischemia
[17]. E2 also increases bcl-2 in vitro in rat hippocampal neurons and
human NT2 neurons [18,19], while it inhibits expression of pro-
apoptotic BAD (bcl-2-antagonist of cell death) [17,18,19,20].
Additionally, E2 enhances expression of the antiapoptotic
prosurvival factor, survivin in the hippocampus CA1 following
GCI, which facilitates neuronal survival [6]. E2 has also been
shown to enhance expression of brain derived neurotrophic factor
(BDNF) in the brain, which has been implicated as a neuropro-
tective factor and to be important for synaptic plasticity, learning,
and memory [21,22].
In addition to genomic signaling, there is increasing evidence
that rapid nongenomic signaling via membrane localized extra-
nuclear ER may also play a role in mediating E2 neuroprotective
effects in the brain [23,24,25]. Along these lines, several
laboratories have shown that the rapid activation of extracellular
signal-regulated kinases 1,2 (ERKs) by E2 is critical for its
neuroprotective effects, as administration of a MEK inhibitor
blocks E2 neuroprotection in neurons in vitro [24,25,26].
Furthermore, E2-induces ERK activation in the CA1 region after
GCI, which is critical for its neuroprotective effects as treatment
with a MEK inhibitor blocked E2-induced ERK activation and E2
neuroprotection in the hippocampus [27] Likewise, a role for the
prosurvival serine kinase Akt in E2 neuroprotection has been
implicated, as E2 rapidly up-regulates Akt activation in cortical
neurons in vitro [28], and in the hippocampus CA1 in vivo following
GCI [29], while treatment with a PI3K inhibitor attenuates the
neuroprotective effects of E2 both in vitro and in vivo [28,29]. In
addition, we recently demonstrated that E2 attenuates the rapid
activation of the proapoptotic signaling kinase, JNK in the
hippocampal CA1 region after GCI [6]. As a whole, these
findings suggest that E2-induced rapid nongenomic signaling may
play a critical role in E2 neuroprotection.
However, since the above studies principally used E2, which can
activate both extranuclear and nuclear estrogen receptors, it has
been difficult to distinguish the importance and contribution of
extranuclear receptor-mediated signaling in E2 neuroprotective
effects. To address this issue, the current study employed two E2
conjugates, E2-BSA conjugate [30,31,32] and the newer E2
dendrimer conjugate (EDC) [33], which due to their size and
charge cannot enter the cell nucleus. EDC and E2-BSA retain
their ability to induce rapid extranuclear-mediated nongenomic
signaling, but lack significant nuclear ER-mediated genomic
signaling ability due to their inability to enter the cell nucleus
and interact with nuclear ER [32,33]. Thus, their use has the
potential to provide important insight into the role and importance
of extranuclear estrogen receptors in E2 neuroprotective effects in
cerebral ischemia. The results of our study reveal that EDC and
E2-BSA administered intracerebroventrically (icv) rapidly activates
ERK, Akt and CREB signaling pathways in the hippocampus,
enhances levels of the CREB transcriptional target, brain-derived
neurotrophic factor (BDNF), strongly protects the hippocampal
CA1 region against neuronal cell death, and significantly improves
hippocampal-dependent cognitive function in the Morris water
maze following GCI. The study thus provides important new
evidence of a critical role for extranuclear estrogen receptor
activation in estrogen-induced neuroprotection and improved
functional cognitive outcome following GCI, and suggests that
ERK-Akt-CREB-BDNF signaling is an important component
mediating extranuclear estrogen receptor beneficial neural effects.
Materials and Methods
Materials
Rabbit polyclonal anti-p-Akt1 (Ser47, sc-7985-R), anti-p-JNK
(Thr183/Tyr185, sc-12882-R), anti-JNK (sc-572), anti-Actin (sc-
10731), goat polyclonal anti-Akt (sc-7126), and anti-ERK (sc-94-
G) antibodies were acquired from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Rabbit anti-p-ERK1/2 (pTpY185/187,
44-680G) was from Biosource (Camarillo, CA, USA). Mouse
monoclonal anti-NeuN (MAB377) was acquired from Millipore
(Billerica, MA, USA). Rabbit p-CREB (Ser133, #9189) and
mouse CREB (#9104) were from Cell Signaling Technology
(Beverly, MA, USA). The secondary antibodies used were goat
anti-rabbit IgG, goat anti-mouse IgG, and donkey anti-goat IgG
and were from Sigma Chemical Co. (St. Louis, MO, USA).
Dimethylsulfoxide (DMSO) was also from Sigma. Alexa Fluor 594
donkey anti-mouse IgG (A21203), Alexa Fluor 488 donkey anti-
rabbit IgG (A21206) and Alexa Fluor 488 donkey anti-goat IgG
(A11055) were purchased from Invitrogen (Carlsbad, CA, USA).
PD98059, LY 294,002 and ICI 182,780 were purchased from
Tocris Cookson, Inc (St. Louis, MO, USA). NBT/BCIP was
obtained from Promega Corporation (Madison, WI, USA).
Methods
Global cerebral ischemia. Adult Sprague Dawley female
rats weighting 250-300g were used throughout the study. All
procedures were approved by the Medical College of Georgia
institutional committee for care and use of animals and were in
accordance with National Institutes of Health guidelines. The rats
were bilaterally ovariectomized under anesthesia, and one week later
four-vessel occlusion (4-VO) cerebral ischemia was carried out.
Briefly, under anesthesia with chloral hydrate (350 mg/kg, i.p.),
vertebral arteries were permanently electrocauterized with a
monopolar coagulator through the alar foramens of the first
cervical vertebra. Common carotid arteries were exposed through
the ventral midline cervical incision and ligatures were placed
loosely around each artery without interrupting the carotid blood
flow. On the next day, under light halothane anesthesia, the
common carotid arteries were re-exposed and occluded with
aneurysm clips to induce forebrain ischemia. After 10 min
ischemia, blood flow was restored by releasing the clips. Criteria
for forebrain ischemia were: completely flat electroencephalographs,
maintenance of dilated pupils, absence of a cornea reflex when
exposed to strong light stimulation, and maintenance of rectal
temperature at about 37uC. Those not matching the criteria or with
seizures were excluded. Sham animals received the same surgical
procedures except bilateral carotid arteries were not occluded.
Morris water maze test. The spatial learning and memory
of the rats were evaluated by Morris water maze as described
previously [34,35]. The maze consisted of black circular pool
(diameter 2.14 m, height 80 cm, filled with water at 21–22uCt oa
height of 50 cm). The pool was divided into four zones by the
software with a hidden platform (9 cm in diameter, 1.5–2.0 cm
below the water line) placed in one of the zones. The rat was
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four (north, south, east and west, locating at equal distances from
each other on the pool rim). Each rat was allowed to find the
submerged platform within 90s, and rest on it for 20s. If the rat
failed to find the hidden platform within 90s, it was placed on the
platform for 20s. The procedure was repeated for all the four start
locations. The latency time, representing the average of the four
trails, to reach the platform and distance were recorded. Two
sessions of four trails were conducted on the first testing day, and
the interval was 4h. The first session was considered as training
procedure. The second was formal testing and was conducted
daily on the next 2 days. Four hours after the last trail, a probe
trail was performed within 90s in which the platform was removed
from the tank. The rat was placed in the water at the same random
start location, and time spent in the quadrant of the pool, which
previously contained the platform were used to assess performance
of learning and memory of the rats.
Sample preparation. The rats were sacrificed under
anesthesia at 10, 30min, 3h, 6h or 1 day after ischemia. The
hippocampal CA1 region was micro-dissected from both sides of
the hippocampal fissure at 0uC and quickly frozen in liquid
nitrogen. Tissues were homogenized in a 1:10 (w/v) ice-cold
homogenization buffer for 10 min consisting of 50 MOPS (mM,
PH 7.4), 150 NaCl, 20 b-glycerophosphate, 3 DTT, 2 Na3VO4,1
EGTA, 1 EDTA, 1 NaF, 1% Triton X-100, 1% NP-40 and
inhibitors of proteases and enzymes (0.5 mM PMSF, 10 mg/ml
each of aprotinin, leupeptin, and pepstatin A). This was followed
by centrifugation at 15,0006g for 15 minutes. The supernatant
was removed and stored at 280uC until use. The protein
concentrations were determined using a BCA protein assay kit
with bovine serum albumin (BSA) as standard.
Western blotting. 100 mg protein of each sample was heated
at 100uC for 5min with loading buffer containing 0.125 M Tris-
HCL (PH 6.8), 20% glycerol, 4% SDS, 10% mercaptoethanol and
0.002% bromphenol blue, then separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 10%
acrylamide gels. The proteins were transferred onto PVDF
membranes (pore size, 0.45 mm). Blotting membranes were
incubated with 3% BSA in TBST (10 mmol/L Tris (PH 7.5),
150 mmol/L NaCl, 0.05% Tween-20) and probed with
corresponding primary antibodies at 4uC overnight. Use alkaline
phosphatase conjugated monkey anti-goat IgG or goat anti-rabbit
or rabbit anti-mouse IgG as secondary antibodies and BCIP/NBT
as color substrate. The bands on the membranes were scanned
and analyzed with an image analyzer (Labworks Software, UVP
Upland, CA, USA). Phospho-protein signals were expressed as a
ratio to the corresponding total protein, and the total proteins were
expressed relative to actin in the same sample. Normalized means
were then expressed relative to the ratio for sham-treated animals.
Histochemical analysis of neuroprotection. After 7 days
of reperfusion period, the animals were deeply anesthetized with
chloral hydrate and transcardially perfused with 0.9% saline,
followed by 4% paraformaldehyde in 0.1 M phosphate buffer (PB,
pH 7.4). Brains were post-fixed in the same fixative at 4uC for 12h,
cryoprotected in 30% sucrose in PB and then were cut
longitudinally into 25mm sections with a cryostat. NeuN staining
was performed as described previously by our laboratory [6,15].
Briefly, sections were washed with 0.1% PBS-Triton X-100 for
365min and permeabilized with 0.4% Triton X-100 in PBS for
10min. After incubation with blocking solutions containing 10%
normal donkey serum for 1h at room temperature in PBS
containing 0.1% Triton X-100, sections were incubated in
primary antibodies (mouse anti-NeuN, 1:200) for 48h at 4uC.
Sections were washed for 3610 min, followed by incubation with
Alexa Fluor 594 donkey anti-mouse antibody (1:200) for 1h at
room temperature. Sections were then washed for 465min with
PBS-Triton X-100, then PBS, and finally with water, and
mounted using water-based mounting medium. Images were
captured on a Confocal Laser Scanning Microscope (Olympus
FV1000). The number of NeuN-positive CA1 neurons per 1 mm
length of the medial CA1 pyramidal cell layer was counted
bilaterally in five sections per animal. Cell counts from the right
and left hippocampus on each of the five sections were averaged to
provide the mean value. A mean6SD was calculated from the
data in each group and statistical analysis performed as described
below.
Confocal Microscopy. Coronal sections were permeabilized
using 0.4% Triton X-100-PBS for 10 min. Sections were then
incubated for 30 min in 10% donkey serum, followed by overnight
incubation at 4uC with primary antibodies - mouse anti-NeuN
(1:200) and rabbit anti-p-Akt (1:50), or mouse anti-NeuN (1:200)
and rabbit anti-p-ERK1/2 (1:50), or mouse anti-NeuN (1:200) and
goat anti-p-JNK. Sections were then washed for 30 min in 0.1%
Triton X-100-PBS and incubated with different secondary
antibodies (Alexa Fluor 594 donkey anti-mouse IgG and Alexa
Fluor 488 donkey anti-rabbit IgG or Alexa Fluor 488 donkey anti-
goat IgG) at room temperature for 1 h, followed by a final wash
for 30 min in PBS. Sections were placed on slides and covered
with mounting medium containing antifading agents (Biomeda;
Thermo Fischer Scientific). Images were obtained using an
Olympus FV1000 laser scanning confocal microscope.
Administration of drugs. EDC (10 mMi n5ml saline), E2-
BSA (10 mMi n5ml saline), or vehicle were bilaterally infused into
the lateral ventricles (from the bregma: anteroposterior, 60.8 mm;
lateral, 1.5 mm; depth, 3.5 mm) 60min before induction of GCI.
The estrogen receptor antagonist ICI182,780 (50 mg), the MEK
and PI3K inhibitors PD98059 (10 mg), LY294002 (25 mg) in 5 ml
1% DMSO respectively were administered icv 10min prior to
EDC or E2-BSA treatment. A volume of 1ml each was infused over
5 min. Following injection, the needle was left in situ for 5min.
The same volume of 1% DMSO or saline served as vehicle
control.
Statistical Analysis. Statistical analysis of the results was
carried out by one-way analysis of variance (ANOVA), followed by
the least significant (LSD) or Student-Newman-Keuls tests. In all
cases, p,0.05 was considered significant. Data was expressed as
mean6SD.
Results
Extranuclear/membrane localization of EDC and E2-BSA
in hippocampal CA1 cells after icv injection and
enhanced neuronal survival and cognitive outcome in
EDC- and E2-BSA-treated rats following global cerebral
ischemia (GCI)
Figure 1A shows localization of FITC-tagged EDC and E2-
BSA conjugates in the hippocampal CA1 region at 60 min
following icv injection in the lateral ventricle of ovariectomized
female rats. As shown in Fig.1A (a), FITC-EDC and FITC-E2-
BSA conjugates are heavily localized in the CA1 after icv injection,
displaying a punctuate extranuclear/membrane pattern of local-
ization. Figure 1A (b&c) shows the neuroprotective ability of
EDC and E2-BSA administered icv 60 min prior to GCI.
Examination of NeuN-positive cells at 7d after GCI revealed that
Vehicle-treated animals that underwent 10-min GCI displayed a
significant loss of NeuN-positive cells in the hippocampal CA1
region as compared to Sham controls. Intriguingly, the cell
impermeable E2 conjugates, EDC and E2-BSA both exerted
Estrogen Signaling
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mediated by ER, as pretreatment with the ER antagonist,
ICI182,780 completely abolished the neuroprotective effect of
both EDC and E2-BSA. We next examined the effect of EDC
upon functional outcome following GCI by examining EDC effect
upon spatial learning and memory in rats 7–9 days after
reperfusion using the Morris water maze (Figure 1B, a–c). As
shown in Fig 1B (a), Vehicle-treated animals that underwent GCI
showed significant higher latencies in finding the submerged
platform on days 7–9 post stroke as compared to sham control
rats. In contrast, EDC-treated rats had significantly decreased
latencies to find the submerged platform on day 7–9 as compared
to the Vehicle group, an effect that was significantly reversed by
the ER antagonist ICI182,780. Furthermore, Fig. 1B (b) shows
that Vehicle-treated animals spent significantly less time in the
quadrant where the submerged platform was located as compared
to sham animals on Day 9. In contrast, EDC-treated rats spent
significantly greater amount of time in the quadrant where the
submerged platform was located as compared to Vehicle group,
and this effect was significantly reversed by the ER antagonist,
ICI182,780, suggesting ER mediation of the cognitive enhancing/
preservation effect of EDC. Finally, representative sample paths
for the various groups and treatments for the maze and probe
trials at 9 days reperfusion are provided in Fig. 1B (c), which
illustrates that EDC-treated animals in the probe trials spent
significantly more time in the quadrant where the platform was
located.
EDC and E2-BSA neuroprotective effects against GCI are
mediated by ERK and Akt signaling pathways
p-Akt. We next examined the extranuclear/membrane
signaling pathways regulated by EDC and E2-BSA, with a focus
on two known pro-survival kinases, Akt and ERK, and a pro-death
kinase, JNK. As shown in Fig. 2A–B, a time course study revealed
that p-Akt levels in the CA1 increased slightly but significantly
from 10min - 6h following reperfusion, with a fall back to sham
levels at 1d reperfusion. Total Akt and b-actin levels did not
change at any time point. EDC treatment led to a significant
elevation of p-Akt levels in the CA1 from 10min - 3h, with a fall
back to sham levels at 1d. Fig. 2C shows that E2-BSA similarly
enhances p-Akt levels at 10 min after reperfusion following GCI,
while total Akt levels were unchanged. Fig. 2D, shows
representative double immunohistochemistry results for NeuN
and p-Akt in the CA1 region at 10 min reperfusion after GCI. The
results mirror the Western blot results observed in Fig 2A–C, with
10 min reperfusion increasing p-Akt levels slightly, with a more
robust increase of p-Akt staining observed following EDC and E2-
BSA treatment. Note also the p-Akt induction is colocalized with
NeuN, suggesting that the elevation of p-Akt by EDC and E2-BSA
occurs in neurons in the hippocampal CA1 region.
p-ERK. Fig. 3A–D shows the effect of EDC and E2-BSA
upon p-ERK levels in the CA1 region after GCI. As shown in
Fig. 3A–B, reperfusion had a biphasic elevation of p-ERK levels
in the CA1 after GCI, with an initial 2-fold increase over sham
observed at 10min, followed by a fall back to sham levels from 3h–
6h, and a second elevation of p-ERK at 1d. It should be noted that
p-ERK1 and p-ERK2 changed in parallel in our study, and that
total ERK levels showed no change at any timepoint. EDC
treatment significant increased p-ERK levels in the CA1 region
from 10 min - 6h, as compared to the reperfusion or vehicle
control. Fig. 3C shows that E2-BSA has a similar enhancing effect
upon p-ERK levels in the CA1 region at 10min reperfusion
following GCI. Confocal analysis of double immunohistochemistry
for NeuN and p-ERK confirmed the Western blot results,
demonstrating that EDC and E2-BSA markedly enhance p-
ERK levels in the CA1 at 10min reperfusion after GCI, with the
increase in p-ERK occurring in CA1 neurons (Fig. 3D).
p-JNK. We next examined EDC and E2-BSA upon activation
of JNK, a proapoptotic factor. Fig. 4A–B shows that p-JNK levels
are increased at all times after reperfusion as compared to sham,
except for the 3h time point which was not significantly elevated.
Total JNK levels did not change regardless of time or treatment.
EDC significantly inhibited p-JNK levels at all time points following
GCI, except the 3h time point where p-JNK levels were not elevated
following reperfusion. E2-BSA also significantly inhibited the
elevation of p-JNK at 10min after reperfusion, while having no
effect upon total JNK levels (Fig. 4C). Confocal analysis of NeuN
and p-JNK double immunostaining confirmed the EDC and E2-
BSA attenuation of p-JNK elevation at 10min reperfusion following
GCI, and further demonstrated that the elevation of p-JNK
occurred predominantly in CA1 neurons, although some non-
NeuN positive cells also showed p-JNK staining as well (Fig. 4D).
Inhibition of ERK and PI3K-Akt Signaling Abolishes EDC
and E2-BSA Neuroprotection. We next examined the role of
ERK and PI3K-Akt signaling in mediating EDC and E2-BSA
neuroprotection following GCI. Fig. 5A shows that EDC and E2-
BSA enhancement of p-ERK levels in the CA1 region at 10min
reperfusion after GCI is abolished by pretreatment with the MEK
inhibitor, PD98059. Likewise, pretreatment with the PI3K
inhibitor, LY294002 markedly attenuated the ability of EDC
and E2-BSA to enhance p-Akt levels in the CA1 region at 10min
reperfusion after GCI (Fig. 5B). A functional role for ERK and
Akt signaling in EDC and E2-BSA neuroprotection against GCI is
suggested by the findings in Fig. 5C (a,b), in which pretreatment
with PD98059 or LY294002 markedly attenuated EDC and E2-
BSA neuroprotection, as demonstrated by NeuN staining
(Fig. 5C,a) and number of NeuN-positive cells (Fig. 5C,b)i n
the hippocampal CA1 region. Furthermore, as shown in Fig. 6,
additional work suggests that EDC and E2-BSA regulatory effects
upon ERK, Akt and JNK activation after GCI are mediated by
estrogen receptors, as pretreatment with the ER antagonist,
Figure 1. (A-a) Extranuclear localization of EDC and E2-BSA in neurons in hippocampal CA1 region of the rats. FITC-tagged EDC and
E2-BSA were injected into the lateral ventricles, and 1h later, the rats were underwent transcardial perfusion and cut into 25mm coronal brain sections
with a cryostat. Confocal analysis showed that EDC and E2-BSA entered neurons in the hippocampal CA1 region but are incapable of penetrating into
the nucleus. (A-b,c) EDC and E2-BSA2 protect neurons of the hippocampus CA1 region from injury induced by GCI. NeuN
immunostaining of representative hippocampus sections from sham, vehicle, EDC, EDC+ICI, E2-BSA and E2-BSA+ICI-treated female ovariectomized
rats subjected to 10min GCI followed by 7d reperfusion. Global ischemia induced significant neuronal cell loss in the CA1 pyramidal cell layer. EDC or
E2-BSA treatment afforded nearly complete protection from global cerebral ischemia-induced neuronal cell loss. ICI182,780 (ICI) abrogated the
neuroprotection induced by EDC or E2-BSA. NeuN-positive neurons in per 1 mm length of CA1 region was counted as surviving neurons.
F(5,30)=105,
*p,0.001 vs. vehicle and EDC+ICI groups; F(5,30)=105,
#p,0.001 vs. vehicle and E2-BSA+ICI groups. Magnification 406; Scale bar 50mm.
(B) Effects of EDC on spatial learning and memory ability in the Morris water maze. (a) Latency to find the submerged platform.
F(11,48)=77,
*p,0.001 vs. sham; F(11,48)=77,
#p,0.001 vs. Vehicle and EDC+ICI. (b) Time spent in the quadrant, which initially contains the platform.
F(3,16)=37,
*p,0.001 vs. sham; F(3, 16)=37,
#p,0.01 vs. Vehicle and EDC+ICI. (c) Representative sample paths from the maze trials (i–iv) and the
probe trials (v–viii) at 9 days after reperfusion. (i,v: sham; ii,vi: vehicle; iii,vii: EDC; iv,viii: EDC+ICI). R: reperfusion. ICI: ICI182,780.
doi:10.1371/journal.pone.0009851.g001
Estrogen Signaling
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e9851ICI182,780 abolished EDC and E2-BSA modulation of ERK, Akt
and JNK activation in the CA1 region at 10min reperfusion.
Activation of CREB and enhanced levels of BDNF by EDC
following GCI
We next examined whether EDC could regulate activation of
the transcription factor, CREB, and its transcriptional target
BDNF in the hippocampal CA1 region after GCI. As shown in
Fig. 7A, EDC rapidly increased pCREB levels in the CA1 region
10min post reperfusion, with a subsequent increase at 3h, 6h and
1d as compared to sham and vehicle controls. E2-BSA also
increased pCREB levels similar to EDC at 10min post-
reperfusion. The early elevation of pCREB levels by EDC, was
followed by elevation of its transcriptional target, BDNF at latter
Figure 2. Effects of EDC and E2-BSA on activation of Akt following cerebral ischemia in the hippocampal CA1 region. (A) Time
courses of p-Akt and Akt, as well as the effects of EDC. Rats were subjected to 10min ischemia followed by 10min, 30min, 3h, 6h and 1d reperfusion.
Bands corresponding to p-Akt were scanned and the intensities represented as values were shown in (B). F(11,36)=19,
*p,0.05 vs. sham;
F(11,36)=19,
#p,0.05, significant difference vs. Vehicle. (C) Effect of E2-BSA on Akt activation at 10min of reperfusion. F(3,12)=20,
*p,0.01 vs. sham;
F(3,12)=20,
#p,0.05 significant difference vs. Vehicle. (D) Confocal analysis of NeuN and p-Akt immunostaining in hippocampus CA1 at 10min
reperfusion after GCI. Sham(a,b,c); vehicle(d,e,f); R10min+EDC(g,h,i); R10min+E2-BSA(j,k,l). Magnification 406; Scale bar 50mm.
doi:10.1371/journal.pone.0009851.g002
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region. Fig. 7B&C illustrates the effect of the PI3K and MEK
inhibitor on EDC enhancement of pCREB and BDNF levels in
the hippocampal CA1 region at 10min and 6h after reperfusion.
As shown in Fig 7B&C, administration of the PI3K or MEK
inhibitor markedly attenuated EDC-induced pCREB elevation in
the CA1 region at 10min and 6h after reperfusion, as well as
significantly attenuated the EDC-induced BDNF elevation at 6h
after reperfusion, suggesting that PI3K-Akt and MEK-ERK
signaling pathways mediate the EDC-induced elevation of pCREB
and BDNF in the hippocampus following GCI.
Discussion
The results of the current study provides evidence that
activation of extranuclear estrogen receptors by E2 conjugates
EDC and E2-BSA rapidly induces activation of a ERK-Akt-
CREB-BDNF signaling pathway and results in neuroprotective
Figure 3. Effects of EDC and E2-BSA on phosphorylation level and protein expression of ERK1/2 following cerebral ischemia in the
hippocampal CA1 region. The time-course of p-ERK1/2 and the effect of EDC were shown in Fig. 3A. Rats were subjected to 10min ischemia
followed by 10min, 30min, 3h, 6h and 1d reperfusion. (B) Bands corresponding to p-ERK1/2 were scanned and the intensities represented as values.
F(11,36)=41,
*p,0.001 vs. sham; F(11,36)=41,
#p,0.05 vs. Vehicle. (C) Effect of E2-BSA on p-ERK1/2 at 10min of reperfusion. F(3,12)=22,
*p,0.05 vs.
sham; F(3,12)=22,
#p,0.001 vs. Vehicle. (D) Confocal analysis of NeuN and p-ERK1/2 immunostaining in hippocampus CA1 at 10min reperfusion
after global cerebral ischemia. Sham(a,b,c); vehicle(d,e,f); R10min+EDC(g,h,i); R10min+E2-BSA(j,k,l). Magnification 406; Scale bar 50mm.
doi:10.1371/journal.pone.0009851.g003
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following GCI. Use of fluorescent-labeled EDC and E2-BSA
conjugates confirmed that the conjugates exhibit an extranuclear/
membrane localization pattern, and do not enter the nucleus after
icv injection. Some cells also showed come cytoplasmic staining/
localization of the E2 conjugates. This finding agrees with previous
work in vitro demonstrating that the E2 conjugates localize
principally to the membrane with some cytoplasmic localization
and are unable to enter the nucleus and activate nuclear ER, but
are potent activators of rapid membrane signaling pathways
[32,33]. That the rapid signaling effects of EDC and E2-BSA
observed in our study are mediated by estrogen receptors was
evidenced by the fact that they were blocked by administration of
the ER antagonist, ICI182,780.
Currently, it is unclear which extranuclear estrogen receptor
mediates the rapid effects of E2 or the E2 conjugates used in our
study. Work by Levin’s group [36,37] has shown that ERa and
ERb can exist as dimers in the plasma membrane of cells, and that
COS-7 cells engineered to express ERa and ERb display
localization of ,2–5% of ERa and ERb protein to the plasma
Figure 4. Effects of EDC and E2-BSA on phosphorylation level of JNK following cerebral ischemia in the hippocampal CA1 region.
(A) Time courses of p-JNK and JNK, as well as the effects of EDC. Rats were subjected to 10min ischemia followed by 10min, 30min, 3h, 6h and 1d
reperfusion. Bands corresponding to p-JNK were scanned and the intensities represented as values are showed in (B). F(11,36)=24,
*p,0.05 vs. sham;
F(11,36)=24,
#p,0.05 vs. Vehicle. (C) Effect of E2-BSA on p-JNK at 10min of reperfusion. F(3,12)=9,
*p,0.05 vs. sham; F(3,12)=9,
#p,0.05 vs.
Vehicle. (D) Confocal analysis of NeuN and p-JNK immunostaining in hippocampus CA1 at 10min reperfusion after global cerebral ischemia.
Sham(a,b,c); vehicle(d,e,f); R10min+EDC(g,h,i); R10min+E2-BSA(j,k,l). Magnification 406and Scale bar 50mm.
doi:10.1371/journal.pone.0009851.g004
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targeted to the plasma membrane. Additional work demonstrated
that palmitoylation of ERa and ERb and interaction with the
scaffold protein, caveolin-1, are key mechanisms for targeting ERa
and ERb to the plasma membrane [38,39]. These studies were
conducted in non-neuronal cells, however, western blot, immu-
nohistochemical and surface biotinylated protein studies have
confirmed the presence of both ERa and ERb at the plasma
membrane of neurons in the in various brain regions including the
hippocampus, and at other extranuclear sites, such as in dendrites
and spines [40,41,42,43,44,45,46]. Furthermore, membrane
localization of ERa and ERb has been demonstrated in glia cells
in different brain regions [43,45,47,48], and glia cells have also
been implicated to participate in mediating estrogen neuropro-
tection via the release of growth factors and neuroactive steroids
[49,50,51]. While in our study, we did not perform GFAP staining
to determine whether astroglial cells had FITC-EDC membrane
labeling, we did observe some cells in the hippocampus with
typical glia morphology that displayed FITC-EDC membrane
labeling. Thus, this supports the possibility that E2 may also act on
glial cells to facilitate its neuroprotective protective effects, as
suggested by others previously [49,50,51]. However, the role of
Figure 5. Effects of PD98059 and LY294002 on neuroprotective role by E2-BSA and EDC following cerebral ischemia in
hippocampal CA1 region. (A) Effects of PD on p-ERK1/2 level at 10min of reperfusion in rats pre-treated with EDC or E2-BSA. F(4,15)=121,
*p,0.001 vs. sham; F(4,15)=121,
*p,0.001 vs. Vehicle. (B) Effects of LY on p-Akt level at 10min of reperfusion in rats pre-treated with EDC or E2-BSA.
F(4,17)=54,
*p,0.001 vs. sham; F(4,17)=54,
#p,0.05 vs. Vehicle. (C) NeuN immunostaining showed the effects of PD or LY on surviving neurons of
the hippocampal CA1 region in rats treated with EDC or E2-BSA and subjected to 10min ischemia followed by 7d reperfusion (Fig. 5C, panel a). NeuN-
positive neurons in per 1mm length of CA1 region was counted as vital survival neurons as shown in Fig. 5C, panel b. F(7,32)=68,
*p,0.001 vs.
vehicle group; F(7,32)=68,
#p,0.001 vs. groups pre-treated with EDC or E2-BSA. PD: PD98059, LY: LY294002, Veh: vehicle.
doi:10.1371/journal.pone.0009851.g005
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using neuron-specific and microglia-specific ERa knockout mice
found that E2 neuroprotection in the cerebral cortex against focal
cerebral ischemia was markedly attenuated only in the neuron-
specific ERa knockout mice and not in the microglia-specific ERa
knockout mice, suggesting that E2 may in part, act directly upon
neurons to exert neuroprotection against ischemia [52]. However,
the study did not examine the hippocampus, and also did not
study astrocyte-specific ERa knockout mice or the role of ERb,
and thus further studies are needed to address this issue more
completely.
Based on the above studies showing that both ERa and ERb
can be localized to the membrane, either extranuclear ERa or
ERb could mediate E2 rapid signaling and neuroprotective effects
in the hippocampus. Use of ERa- and ERb-selective agonists has
provided evidence that activation of either ERa or ERb could lead
to enhanced neuroprotection following GCI [16]. However, using
an antisense oligonucleotide knockdown approach, our group
found that only knockdown of ERa, but not ERb in the
hippocampal CA1 region, significantly attenuated E2 rapid
signaling and neuroprotective effect following GCI [15], which
suggests that ERa may be more important in mediating the E2
signaling and neuroprotective effects in the hippocampus.
However, we can’t completely rule out a role for membrane
ERb, as the antisense knockdown only achieved a 50–60%
knockdown of the ERb protein in that study and a greater
reduction may be needed to determine conclusively a role or non-
role of ERb. However, use of ER knockout mice revealed that E2
neuroprotection in focal cerebral ischemia was unaffected by
complete whole animal knockout of ERb, while, in contrast, ERa
knockout mice had a dramatic loss of E2 neuroprotection [13],
further supporting a critical role for ERa in E2 neuroprotective
effects. Finally, it is also possible that the newly identified putative
G-protein-coupled estrogen receptor, GPR30, could have a role in
mediating E2 rapid signaling and neuroprotective effects [53,54].
In support of this possibility, preliminary studies by our lab found
that icv administration of antisense oligonucleotides to GPR30
significantly attenuated E2 rapid signaling and neuroprotection
following GCI (unpublished observations). Thus, in addition to
extranuclear ERa, extranuclear GPR30 may also participate in
mediating estrogen rapid signaling and neuroprotective effects in
the hippocampus. Interestingly, studies in pancreatic beta cells
similarly revealed a role for both extranuclear ERa and GPR30 in
mediating E2 protection of pancreatic beta cells from streptozot-
ocin-induced apoptosis [55].
While our data demonstrates a potent effect of EDC (and E2-
BSA) in inducing rapid nongenomic signaling, one should not
construe that EDC only activates a nongenomic signaling pathway
and is incapable of exerting genomic effects. Work by Katzenel-
lenbogen and coworkers [56] clearly showed that EDC could
regulate gene expression in cells in vitro and that the effect did not
involve interaction with or activation of nuclear ER genomic
signaling. Rather, EDC effected changes in gene expression via its
activation of rapid ERK and Src kinase signaling which can
regulate phosphorylation of transcription factors, histones and
other factors and thereby modulate gene transcription. The study
further showed that EDC was incapable of recruiting nuclear ERa
to estrogen responsive regions of genes, whereas ERa recruitment
by E2 was very effective. Thus, EDC nongenomic signaling can
induce genomic signaling that is independent of nuclear ER.
Intriguingly, previous work by Pfaff and coworkers has also
demonstrated that nongenomic signaling by E2 in the hypothal-
amus can actually potentiate E2 genomic actions to induce
lordorsis behavior [57,58], suggesting that rapid effects of E2 may
also modulate genomic effects of E2.
Interestingly, our own findings revealed that EDC and E2-BSA
enhanced phosphorylation of the transcription factor, CREB in a
rapid fashion following reperfusion, and that this effect is ERK-
and Akt-dependent. Among the best known CREB transcriptional
targets is the growth factor, BDNF, which was shown in our study
to also be elevated by EDC. We also found that a second
transcriptional target of CREB, Bcl-2, a potent antiapoptotic
factor, was also induced by EDC in the hippocampal CA1 region
following ischemic reperfusion (unpublished observation). These
findings raise the possibility that EDC activation of extranuclear
estrogen receptors may involve a nongenomic to genomic
signaling cascade via kinase-induced activation of the transcription
factor, CREB. It should be noted that Etgen and coworkers [59]
previously demonstrated that E2 rapidly elevates pCREB in the
hippocampal CA1 following GCI, while Raval et al [60] found
that higher serum E2 levels on proestrus was correlated with
enhanced pCREB in the hippocampus and increased neuropro-
tection from GCI, further supporting a potentially critical role for
CREB in E2 neural actions. Our study adds to these findings by
demonstrating a role for extranuclear estrogen receptors in CREB
activation via the use of the nuclear impermeable E2 conjugates,
demonstrating the importance of ERK and Akt signaling for
CREB activation and for elevation of BDNF, and demonstrating a
Figure 6. Effects of ICI 182,780 on phosphorylation of Akt,
ERK1/2 and JNK induced by E2-BSA or EDC at 10min of
reperfusion in hippocampal CA1 region. (A) Western blot analysis
showed phosphorylation levels and protein expressions of Akt, ERK1/2
and JNK. Samples were obtained from sham, vehicle, E2-BSA, E2-
BSA+ICI, EDC and EDC+ICI treated animals. Bands corresponding to p-
Akt, p-ERK1/2 and p-JNK were scanned and the intensities represented
as fold increase vs. sham as shown in (B). F(5,18)=106, p,0.01 for p-
Akt; F(5,18)=38, p,0.01 for p-ERK1/2; and F(5,18)=23 for p-JNK.
* indicates vs. E2-BSA groups without ICI,
# indicates vs. EDC groups
without ICI. ICI: ICI 182,780.
doi:10.1371/journal.pone.0009851.g006
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Akt-CREB-BDNF signaling pathway in preserving cognitive
function following GCI.
In addition to enhancing activation of the well-known pro-
survival factors, ERK, Akt and CREB, our study demonstrated
that EDC exerted a prolonged attenuation of phosphorylation of
JNK at Thr183/Tyr185, phosphorylation sites known to be critical
for JNK activation [61]. JNK is known to phosphorylate many
cellular proteins, including several implicated in apoptosis, and can
translocate to the nucleus to activate c-Jun and AP-1-mediated
gene transcription, leading to transcription of pro-death genes
[62]. Previous work by our group and others has shown that
administration of a JNK inhibitor [6,63] or knockout of JNK [64]
results in profound protection of the brain against cerebral
ischemia, further demonstrating a key pro-apoptotic role of JNK
in ischemic neuronal cell death. Thus, the ability of EDC to
markedly attenuate JNK activation after GCI likely contributes
significantly to its neuroprotective actions.
Finally, with respect to the cognitive preserving effects of EDC,
it is suggested that EDC activation of CREB and its ability to
increase BDNF in the hippocampal CA1 region likely plays a
significant role in preservation of cognitive function following
GCI. Both CREB and BDNF have been implicated in
neuroprotection, as well as in facilitating learning and memory
[21,65,66,67,68,69]. It should be noted that the enhanced
expression of BDNF by EDC was delayed in our study as compared
to the CREB activation, as BDNF elevation occurred at 6–24h
after reperfusion, while pCREB elevation occurred as early as
10min post-reperfusion. The delayed induction of BDNF could be
explained by the time needed for CREB to enhance transcription
Figure 7. Effects of EDC on protein levels of CREB, p-CREB and BDNF following ischemic reperfusion in the hippocampal CA1
region. (A) Western blot analysis showed the time-courses of p-CREB, CREB and BDNF protein expression, as well as the effects of EDC or E2-BSA.
F(3,16)=31,
*p,0.001 vs. vehicle at the same timepoint. (B–C) Effects of PD or LY on CREB/p-CREB level and BDNF levels at 10min of reperfusion or 6h
reperfusion in rats pre-treated with EDC. B: F(3,16)=23,
*p,0.001 vs. sham; F(3,16)=23,
#p,0.001 vs. EDC group. C: F(3,12)=64,
*p,0.001 vs. sham;
F(3,15)=21,
#p,0.001 vs. EDC group. R: reperfusion, PD: PD98059, LY: LY294002.
doi:10.1371/journal.pone.0009851.g007
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activation of CREB in the CA1 region by EDC following
reperfusion was also observed at multiple time points (10min,
3h, 6h and 24h). This is intriguing and may have functional
importance, as prolonged CREB activation has been correlated
with enhanced neuroprotection in previous studies [65,70].
Finally, one must consider the temporal pattern of the CREB
and BDNF changes to determine the most probable mechanism of
EDC preservation of cognitive function. In our study, these
elevations occurred in the initial 24h time window following
reperfusion, while our examination of cognitive function was 6–9
days later. Considering this, it is most likely that the role of CREB
and BDNF in cognitive preservation in our study is limited to its
neuroprotective actions that reduce ischemic neuronal cell death in
the hippocampal CA1 region following GCI and thereby preserves
cognitive function. However, BDNF has also been implicated to
regulate synaptic plasticity [69], and such a plasticity-regulatory
action in the early post-ischemic reperfusion period (first 24hr)
could help maintain synaptic connections following the ischemic
insult, which also could facilitate preservation of cognitive
function.
In conclusion, the current study provides important new
evidence that activation of extranuclear estrogen receptors with
resultant induction of an ERK-Akt-CREB-BDNF signaling
pathway mediates neuroprotection and preservation of cognitive
function following GCI. The study thus adds to a growing
literature supporting a potentially important role of extranuclear
estrogen receptors in mediating estrogen beneficial effects in the
brain.
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